Kura Oncology, Inc. (NASDAQ:KURA) Holdings Reduced by Foresite Capital Management IV LLC

Foresite Capital Management IV LLC lowered its holdings in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 6.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,726,882 shares of the company's stock after selling 123,065 shares during the quarter. Kura Oncology accounts for about 13.8% of Foresite Capital Management IV LLC's investment portfolio, making the stock its 2nd biggest holding. Foresite Capital Management IV LLC owned 2.22% of Kura Oncology worth $15,041,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Deutsche Bank AG lifted its position in Kura Oncology by 48.6% during the fourth quarter. Deutsche Bank AG now owns 64,623 shares of the company's stock valued at $563,000 after purchasing an additional 21,135 shares during the period. D. E. Shaw & Co. Inc. lifted its holdings in shares of Kura Oncology by 172.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,151,195 shares of the company's stock valued at $10,027,000 after buying an additional 727,987 shares during the period. DAFNA Capital Management LLC boosted its stake in shares of Kura Oncology by 9.8% in the 4th quarter. DAFNA Capital Management LLC now owns 448,368 shares of the company's stock worth $3,905,000 after buying an additional 40,000 shares during the last quarter. Corton Capital Inc. bought a new stake in shares of Kura Oncology in the fourth quarter worth $99,000. Finally, BNP Paribas Financial Markets increased its position in Kura Oncology by 969.9% during the fourth quarter. BNP Paribas Financial Markets now owns 163,559 shares of the company's stock valued at $1,425,000 after acquiring an additional 148,272 shares during the last quarter.

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $5.77 on Friday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 52 week low of $5.41 and a 52 week high of $23.48. The stock's 50-day simple moving average is $6.57 and its 200-day simple moving average is $9.23. The company has a market capitalization of $499.54 million, a price-to-earnings ratio of -2.44 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The company had revenue of $14.11 million during the quarter, compared to the consensus estimate of $39.08 million. As a group, analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on KURA shares. Cantor Fitzgerald raised Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. StockNews.com lowered shares of Kura Oncology from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Wedbush reiterated an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research report on Tuesday, April 8th. Barclays cut their price objective on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Kura Oncology in a report on Monday, April 28th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $23.89.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.